Clinical trial · Interventional
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
CHOICES: A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as hydroxychloroquine, may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether imatinib mesylate is more effective when given with or without hydroxychloroquine in treating patients with chronic myeloid leukemia. PURPOSE: This randomized phase II trial is studying the side effects of giving imatinib mesylate with or without hydroxychloroquine and to see how well it works in treating patients with chronic myeloid leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cytogenetic analysis | Genetic | — | UNRESOLVED |
| hydroxychloroquine | Drug | Hydroxychloroquine | ALIAS |
| imatinib mesylate | Drug | Imatinib Mesylate | ALIAS |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| pharmacological study | Other | — | UNRESOLVED |
| polymerase chain reaction | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Proportion of treatment "successes" defined as patients who have at least 0.5 log reductions or more in their 12-month PCR level from baseline
Secondary outcomes (3)
- measure
- Proportion of treatment "successes" at 24 months
- measure
- Molecular response at 12 and 24 months (complete response, major response, or no response)
- measure
- Proportion of patients with progression at 12 and 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of chronic myeloid leukemia (CML) in chronic phase (CP) * Has been treated with imatinib mesylate for at least 1 year * Receiving a stable dose for ≥ 6 months prior to randomization * Achieved at least major cytogenetic response (MCyR) and continues to be BCR/ABL-positive by quantitative polymerase chain reaction (Q-PCR) * Must have a fusion gene present that can be monitored by Q-PCR PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Absolute neutrophil count ≥ 1,500/mm³ (stable and within normal range for ≥ 2 months) * Platelet count ≥ 100,000/mm³ (stable and within normal range for ≥ 2 months) * Serum albumin \> 3 g/dL * AST and/or ALT ≤ 2.5 times upper limit of normal (ULN) * Serum bilirubin ≤ 1.5 times ULN * Serum creatinine ≤ 1.5 times ULN OR 24-hour creatinine clearance ≥ 50 mL/min * Serum potassium ≥ lower limit of normal with or without replacement therapy * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective double-method contraception (including a barrier method \[i.e., condom\]) during and for 3 months after completion of study therapy * No impaired cardiac function, including any of the following: * QTc \> 450 msec on screening ECG * Congenital long QT syndrome * History or presence of sustained ventricular tachycardia * History of ventricular fibrillation or Torsades de pointes * NYHA class III-IV congestive heart failure * Uncontrolled hypertension * No severe gastrointestinal (GI) disorder, uncontrolled epilepsy, known glucose-6-phosphate dehydrogenase (G6PD) deficiency, known porphyria, moderate or severe psoriasis, known myasthenia gravis, or other concurrent severe and/or uncontrolled medical conditions * No preexisting maculopathy of the eye * No significant history of noncompliance to medical regimens or the inability to grant a reliable informed consent PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 4 weeks since prior chemotherapy, investigational drug, or major surgery and recovered * More than 6 months since change in imatinib mesylate dose * No other concurrent anticancer therapy or radiotherapy
References
Publications (0)
Data not yet available